Cancer Research UK launched a campaign over the Christmas and New Year period to ensure that both the public and investors are aware that more investment in research is the key to improving the wellness of our community by finding out the causes of cancers and providing effective screening. This need is especially apparent in the case of prostate cancer, as it is the biggest killer in the UK for men, but has not received much research funding to develop better screening. The early identification of those at high risk of contracting prostate cancer and the employment of the best screening protocols have been a great concern for doctors and scientists today. More research is required if scientists are to find the right area of screening that will ensure prostate cancer is caught early on, and thereby reduce the rare of mortality from this disease.
An example of the success of early screening can be seen in the screening for bowel cancer. The Flexi Scope Test was developed after 16 years of research conducted by Cancer Research UK. Its effect has been highly significant in the field of cancer treatment; it is said to have reduced the mortality rate by 43% and the risk of contracting the disease by a third. It is quite clear that investment into the development of cancer screening processes should be at the top of any health company’s agenda today.